OliX develops RNAi therapeutics using its OASIS (OliX Advanced Small Interfering RNA System) platform designed to enhance gene-silencing efficiency and enable tissue-specific delivery. Using OASIS, the company is advancing programs for indications including hair loss, age-related macular degeneration, hypertrophic scars, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and cardiometabolic disorders. Under its “OliX 2.0 Roadmap,” the company is also developing next-generation delivery technologies targeting the central nervous system and adipose tissue while expanding its pipeline of RNAi-based therapies. The recent financing with BOLD and Weiss is intended to accelerate these development programs and strengthen research capabilities. The partnership with L’Oréal via BOLD is positioned as strategic, combining OliX’s siRNA platform with L’Oréal’s expertise in biology, tech, and formulation. OliX has framed the investment as validation of its technological competitiveness and growth potential.

Total raised

$72M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2026